Bhc Chicken, one of the major fried chicken franchises in South Korea, is facing criticism for raising the prices of its menu items despite changing ingredients to cheaper brands.
A local consumer advocacy group said that the company shifted to Brazilian chicken, the cheaper ingredient option. Still, the menu was made even more expensive rather than lowering or keeping the prices as they were.
According to Yonhap News Agency, bhc Chicken has been using chicken produced locally, but in May of last year, it decided to use Brazilian chicken. The fried chicken restaurant chain said it made the change due to difficulty in the supply.
Price Difference Between Korean and Brazilian Chicken
Based on the report, Brazilian chicken costs much less than those sourced from local farms and companies. The difference in the prices is more than 50%, but despite this, bhc reportedly raised the prices of its 85 menu items in December 2023.
The hike was also applied to the brand's seven fried boneless chicken items, now KRW500 or $0.38 more expensive. Bhc Chicken said it had to add markups on its prices because of higher prices of ingredients, rental fees, and payroll of staff.
Complaints from Consumer Groups
Alphabiz reported that bhc Chicken is not the only brand to shift to Brazilian chicken and noted that the brand's competitors have started to use chicken from Brazil. However, these companies have not touched their menu prices and have remained unchanged since the second half of 2023.
"It is common sense that the burden of ingredient prices is reduced as Brazilian frozen meat is much cheaper than Korean chicken," an official of the Korea National Council of Consumer Organizations stated. The groups further noted that bhc Chicken has no reason to raise its menu prices.
Photo by: BHC Group Website


Niigata Set to Approve Restart of Japan’s Largest Nuclear Power Plant in Major Energy Shift
FTC Praises Instacart for Ending AI Pricing Tests After $60M Settlement
Roche CEO Warns US Drug Price Deals Could Raise Costs of New Medicines in Switzerland
AstraZeneca’s LATIFY Phase III Trial of Ceralasertib Misses Primary Endpoint in Lung Cancer Study
Trump Signals Push for Lower Health Insurance Prices as ACA Premium Concerns Grow
JPMorgan’s Top Large-Cap Pharma Stocks to Watch in 2026
Trump Administration Reviews Nvidia H200 Chip Sales to China, Marking Major Shift in U.S. AI Export Policy
Maersk Vessel Successfully Transits Red Sea After Nearly Two Years Amid Ongoing Security Concerns
Moore Threads Unveils New GPUs, Fuels Optimism Around China’s AI Chip Ambitions
TikTok U.S. Deal Advances as ByteDance Signs Binding Joint Venture Agreement
U.S. Lawmakers Urge Pentagon to Blacklist More Chinese Tech Firms Over Military Ties
Uber and Baidu Partner to Test Robotaxis in the UK, Marking a New Milestone for Autonomous Ride-Hailing
Dina Powell McCormick Resigns From Meta Board After Eight Months, May Take Advisory Role
ByteDance Plans Massive AI Investment in 2026 to Close Gap With U.S. Tech Giants
Mexico Antitrust Review of Viva Aerobus–Volaris Deal Signals Growth for Airline Sector
Novo Nordisk Stock Surges After FDA Approves Wegovy Pill for Weight Loss 



